Home care—a safe and attractive alternative to inpatient administration of intensive chemotherapies

Lüthi, François; Fucina, Nadia; Divorne, Nathalie; Santos-Eggimann, Brigitte; Currat-Zweifel, Christine; Rollier, Patricia; Wasserfallen, Jean‐Blaise; Ketterer, Nicolas; Leyvraz, Serge

doi:10.1007/s00520-011-1125-9

Cited by 42 publications

(35 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many patients and caregivers prefer the convenience of homeor community-based care, and empirical evidence confirms that several cancer treatments can be safely delivered outside of the hospital (Boothroyd and Lehoux 2004;Luthi et al 2012). Some services are also more cost effective when delivered in the community or in patient homes rather than in hospital (Boothroyd and Lehoux 2004).…”

Section: Focus 2: Care Outside Hospitalsmentioning

confidence: 99%

Integrating Cancer Care Beyond the Hospital and Across the Cancer Pathway: A Patient-Centred Approach

Evans

Matheson

Buchman

et al. 2014

hcq

View full text Add to dashboard Cite

Cancer patients constitute one of the most complex, diverse and growing patient populations in Canada. Like other high-needs patient groups, cancer patients desire a more integrated approach to care delivery that spans organizational and professional boundaries. This article provides an overview of Cancer Care Ontario's experience in fostering a more integrated cancer system, and describes the organization's emerging focus on patient-centred models of integrated care through the whole cancer pathway, from prevention to end-of-life care and survivorship.

show abstract

Section: Focus 2: Care Outside Hospitalsmentioning

confidence: 99%

Integrating Cancer Care Beyond the Hospital and Across the Cancer Pathway: A Patient-Centred Approach

Evans

Matheson

Buchman

et al. 2014

hcq

View full text Add to dashboard Cite

show abstract

“…There is an increasing interest in the administration of cancer treatment outside the hospital based on patient preferences, capacity issues in oncology day care hospitals facing an increasing number of patients and treatments, and the increased use of oral chemotherapy [17]. In a feasibility study of home-based chemotherapy, patient benefits of home care included increased comfort and freedom [18]. All the patients in the BELIS study who completed the questionnaire concerning the quality of care in the hospital and at home indicated that being treated at home with trastuzumab SC was beneficial to a large or very large extent.…”

Section: Discussionmentioning

confidence: 99%

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Denys

Martinez-Mena

Martens

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose The subcutaneous (SC) administration of trastuzumab is highly preferred by patients. At home, administration of trastuzumab SC might further improve patient benefit. The aims of the BELIS study are to evaluate the safety and tolerability of trastuzumab SC when administered at home by a healthcare professional (HCP) and to evaluate patient-reported outcomes for treatment experience of at home cancer therapy. Methods This open-label phase IIIb study enrolled HER2-positive early breast cancer patients in Belgium and Israel who completed the first six cycles of trastuzumab IV (neo)adjuvant therapy. The study consisted of three consecutive treatment periods: three cycles of trastuzumab IV and SC each at the hospital and six cycles of trastuzumab SC at home. Results Between November 2013 and December 2014, 23 centres enrolled 102 patients in the intent-to-treat population of which 101 patients entered the safety population. No new safety signals were detected with as expected, more mild administration site events with trastuzumab SC when compared to IV treatment. All patients agreed that they had benefit from at home administration to a large (18/81; 22%) or very large (63/81; 78%) extent. All HCPs (21/21) agreed that SC is the quickest method from start of preparation to finish of administration and that less resource use is needed. Conclusion The results of the BELIS study support that trastuzumab SC can be safely administered at home by a HCP and all patients considered this setting as beneficial. HCPs consider the SC formulation as the quickest method to administer trastuzumab. Trial registration EudraCT Identifier: 2013-000123-13. ClinicalTrials.gov Identifier: NCT01926886.

show abstract

“…Savings for chemotherapy administered at home has also been demonstrated in solid tumors like colorectal, non-small cell lung cancer with a decrease in expenses of up to 53 % for intensive chemotherapies mainly administered for hematological malignancies [4, 5, 17]. …”

Section: Discussionmentioning

confidence: 99%

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Touati

Lamarsalle²,

Moreau

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

At home injectable chemotherapy for patients receiving treatment for hematological diseases is still in debate. Given the expense of new innovative medicines, at home treatment has been proposed as a suitable option for improving patient quality of life and decreasing treatment costs. We decided to assess the cost of bortezomib administration in France among multiple myeloma patients from an economic standpoint. Patients in this study were treated within a regional hematological network combining outpatient hospital care and Hospital care at Home administration. To make the cost comparison, our team simulated outpatient hospital care expenses. Fifty-four consecutive multiple myeloma patients who received at least one injection of bortezomib in Hospital care at Home from January 2009 to December 2011 were included in the study. The median number of injections was 12 (range 1–44) at home and 6 (range 0–30) in the outpatient care unit. When compared with the cost simulation of outpatient hospital care alone, bortezomib administration with combined care was significantly less expensive for the National Health Insurance (NHI) budget. The mean total cost per patient and per injection was 954.20 € for combined outpatient and Hospital care at Home vs 1143.42 € for outpatient hospital care alone. This resulted in an estimated 16.5 % cost saving (Wilcoxon signed-rank test, p < 0.0001). The greatest savings were observed in administration costs (37.5 % less) and transportation costs (68.1 % less). This study reflects results for a regionally implemented program for multiple myeloma patients treated with bortezomib in routine practice in a large rural area.Electronic supplementary materialThe online version of this article (doi:10.1007/s00520-016-3363-3) contains supplementary material, which is available to authorized users.

show abstract

Home care—a safe and attractive alternative to inpatient administration of intensive chemotherapies

Cited by 42 publications

References 22 publications

Integrating Cancer Care Beyond the Hospital and Across the Cancer Pathway: A Patient-Centred Approach

Integrating Cancer Care Beyond the Hospital and Across the Cancer Pathway: A Patient-Centred Approach

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Contact Info

Product

Resources

About